公司业绩表现 - 公司在最近两个季度持续超出盈利预期，平均超出幅度达11.63% [1] - 最近一个季度，公司每股收益为3.1美元，超出市场预期的3美元，超出幅度为3.33% [2] - 上一季度，公司每股收益为3.67美元，远超市场预期的3.06美元，超出幅度高达19.93% [2] 近期盈利预测动向 - 基于公司过往的盈利历史，近期市场对其盈利预期正在上调 [5] - 公司目前的Zacks盈利ESP（预期惊喜预测）为正值+4.49%，表明分析师对其短期盈利潜力转向乐观 [8] - 盈利ESP指标通过比较“最精确预估”与“共识预估”得出，分析师在财报发布前修正的预估通常包含最新信息 [7] 投资信号与组合表现 - 当公司股票同时具备正值的盈利ESP和Zacks排名第2位（买入）时，预示着其可能再次超出盈利预期 [8] - 研究显示，具备正盈利ESP和Zacks排名第3位（持有）或更好排名的股票组合，有近70%的概率实现盈利正惊喜 [6] - 公司下一次财报预计将于2025年10月22日发布 [8]

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Medpace (MEDP) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Medpace is a member of the Medical sector. This group includes 957 individual stocks and currently holds a Za ...

文章核心观点 - 文章旨在比较Solventum和Medpace两只医疗服务业股票，以判断当前哪个为更好的价值投资机会 [1] - 基于Zacks评级和关键估值指标分析，Solventum可能比Medpace更具价值优势 [7] 公司比较：Zacks评级 - Solventum的Zacks评级为1（强力买入），而Medpace的评级为3（持有） [3] - Solventum的盈利前景改善程度可能强于Medpace [3] 公司比较：估值指标 - 市盈率 - Solventum的远期市盈率为12.56，远低于Medpace的38.33 [5] - Solventum的市盈增长比率为3.03，低于Medpace的3.37 [5] 公司比较：估值指标 - 市净率 - Solventum的市净率为3.54，显著低于Medpace的87.39 [6] - 市净率用于比较股票市值与其账面价值（总资产减总负债） [6] 公司比较：价值评分 - 基于多项估值指标，Solventum的价值评级为B，而Medpace的价值评级为D [6] - 价值评分综合考量了市盈率、市销率、收益收益率及每股现金流等关键基本面指标 [4]

Medpace (MEDP) closed the most recent trading day at $536.17, moving -1.42% from the previous trading session. This change lagged the S&P 500's daily gain of 0.06%. On the other hand, the Dow registered a gain of 0.17%, and the technology-centric Nasdaq increased by 0.39%. Heading into today, shares of the provider of outsourced clinical development services had gained 13.02% over the past month, outpacing the Medical sector's gain of 5.06% and the S&P 500's gain of 3.94%.Investors will be eagerly watching ...

Barclays downgraded Medpace Holdings Inc. (NASDAQ: MEDP) from Equalweight to Underweight and reduced its price target to $425.00 from $450.00. The firm said the downgrade was primarily valuation-driven, noting that Medpace shares were trading well above the premium historically enjoyed relative to peers. While the biotech market was described as “bouncing along the bottom,” Barclays said it expected the company to continue winning new business. However, the firm flagged potential risk in the second half of ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Barclays upgraded Charles River (CRL) to Overweight from Equal Weight with a price target of $195, up from $165. The firm cites stabilized drug discovery demand and valuation for the upgrade.Barclays upgraded C.H. Robinson (CHRW) to Equal Weight from Underweight with a price target of $130, up from $95. The upgrad ...

"Successful investing takes time, discipline, and patience. No matter how great the talent or effort, some things just take time", said Warren Buffett. The question now is - did you have the patience to hold on to stocks we highlighted and reap the gains? Cidara Therapeutics Inc. (CDTX) touched a 52-week high of $87.19 today, as it continues to progress with its accelerated development plan for CD388, a non-vaccine preventive treatment for seasonal influenza. The company will be pursuing a Biologics Licens ...

Madison Investments, an investment advisor, released its “Madison Mid Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund (Class Y) returned 5.2% compared to the 8.5% increase for the Russell Midcap Index. In addition, please check the fund’s top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, the Madison Mid Cap Fund highlighted stocks such as Medpace Holdings, Inc. (NASDAQ:MEDP). Medpace Hold ...

I grant Medpace (NASDAQ: MEDP ) a buy rating. I am of the opinion that there are substantial grounds to believe that the company will continue to generate value for its investors. To begin with, the companyDaniel Mellado is an economist from Carabobo University with a Master's Degree in Statistics from Simon Bolivar University, both obtained in Venezuela.Daniel worked analyzing the agricultural commodity market and the financial investment portfolio for an agribusiness group. Then, he managed two teams, one ...

核心观点 - Cencora和Medpace均为医疗服务业股票且均获Zacks买入评级但Cencora的估值指标显著优于Medpace被认定为更具吸引力的价值投资标的 [1][3][6] 估值指标对比 - Cencora远期市盈率为18.30而Medpace为33.85 [5] - Cencora市盈增长比率(PEG)为1.38显著低于Medpace的2.98 [5] - Cencora市净率为25.49而Medpace高达77.18 [6] 价值评级结论 - Cencora获得A级价值评级而Medpace仅获D级价值评级 [6] - 两家公司均呈现盈利预期上调趋势且均获Zacks买入评级但估值水平差异显著 [3][6]